Stock listing

NASDAQ:REVB Revelation Biosciences, Inc. Stock

Home listing (NASDAQ) of Revelation Biosciences, Inc.

Follow Revelation Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:REVB

$3.50 USD -0.35 (-9.1%)

Close on Nov 20, 2026

Past year -85.3% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$3.50 – $3.80 USDNov 20, 2026
Volume
9,801 sharesNov 20, 2026
Market cap
$2.39M USDAt the close on Nov 20, 2026 · price × 683,442 shares outstanding
52-week range
$3.08 – $40.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$53,652 USDMedian day 6,430 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Revelation Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:REVB · Home$3.50 USD-0.35 (-9.1%)9,801$3.71$3.80$3.50$3.85Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:REVB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$3.50-0.35-9.1%$3.71$3.80$3.509,801
$3.85-0.03-0.8%$3.60$4.23$3.6012,915
$3.88+0.06+1.6%$3.98$3.98$3.7513,259
$3.82-0.445-10.4%$4.00$4.00$3.7128,426
$4.265-0.115-2.6%$4.38$4.50$4.176,430
$4.38+0.02+0.5%$4.27$4.40$4.156,855
$4.36+0.42+10.7%$3.92$4.36$3.9211,466
$3.94-0.17-4.1%$4.07$4.07$3.5779,482
$4.11+0.22+5.7%$4.135$4.50$3.97524,066
$3.89+0.33+9.3%$3.66$3.94$3.5613,950
$3.56-0.558-13.5%$3.755$3.76$3.4314,929
$4.118-0.312-7.0%$4.43$4.43$3.8511,228
$4.43+0.38+9.4%$4.46$4.75$4.2025,827
$4.05+0.02+0.5%$4.00$4.133$3.869,558
$4.03+0.28+7.5%$3.79$4.03$3.7522,064
$3.75+0.03+0.8%$3.63$3.75$3.564,981
$3.72-0.01-0.3%$3.76$3.84$3.729,021
$3.73+0.195+5.5%$3.437$3.73$3.43714,686
$3.535-0.255-6.7%$3.80$3.87$3.3610,746
$3.79+0.11+3.0%$3.68$3.88$3.6616,300
$3.68+0.08+2.2%$3.67$3.85$3.60135,500
$3.60-0.15-4.0%$3.75$3.97$3.5119,500
$3.75+0.467+14.2%$3.30$4.06$3.294156,000
$3.283-0.112-3.3%$3.50$3.57$3.0843,643
$3.395-1.94-36.4%$4.935$4.935$3.26990,743
$5.335+0.297+5.9%$5.215$5.459$5.112,949
$5.038-0.073-1.4%$5.111$5.354$4.973,253
$5.111-0.312-5.7%$5.32$5.39$5.1113,832
$5.423+0.104+1.9%$5.594$5.594$5.391,796
$5.319-0.098-1.8%$5.401$5.716$5.253,542
$5.417-0.379-6.5%$5.67$5.67$5.399,510
$5.797+0.531+10.1%$5.285$5.855$5.2857,284
$5.265-0.174-3.2%$5.558$5.579$5.254,961
$5.44+0.095+1.8%$5.537$5.81$5.32712,947
$5.345-0.262-4.7%$5.67$5.67$5.3456,271
$5.607-0.112-2.0%$5.741$5.852$5.538,687
$5.719+0.021+0.4%$5.781$5.915$5.7174,309
$5.698-0.317-5.3%$6.152$6.152$5.6797,567
$6.015-0.076-1.3%$6.16$6.195$5.814,903
$6.0910.000.0%$6.231$6.364$5.9516,199
$6.091-0.449-6.9%$6.44$6.564$6.01910,798
$6.541-0.319-4.7%$6.761$6.852$6.448,388
$6.86+0.026+0.4%$7.00$7.14$6.7124,134
$6.834+0.321+4.9%$6.79$7.069$6.5112,597
$6.513-0.137-2.1%$6.848$6.892$6.5132,258
$6.65+0.21+3.3%$6.475$6.79$6.444,222
$6.44+0.067+1.1%$6.782$6.782$6.4322,232
$6.373-0.314-4.7%$6.894$6.894$6.375,231
$6.686-0.26-3.7%$6.93$6.93$6.6862,103
$6.947-0.049-0.7%$6.997$7.00$6.931517
$6.996-0.074-1.0%$7.00$7.00$6.996703
$7.070.000.0%$7.14$7.14$7.036372
$7.070.000.0%$7.00$7.28$7.002,287
$7.070.000.0%$7.105$7.28$6.931,105
$7.07+0.07+1.0%$7.21$7.28$6.932,851
$7.00+0.094+1.4%$6.93$7.28$6.932,571
$6.906-0.094-1.3%$7.076$7.23$6.8763,602
$7.00-0.35-4.8%$7.42$7.42$7.001,842
$7.35+0.14+1.9%$7.28$7.56$7.0012,901
$7.21+0.525+7.9%$6.803$7.21$6.6862,996
$6.685-0.315-4.5%$6.861$7.07$6.655,226
$7.00-0.70-9.1%$7.63$7.70$6.3728,580
$7.70+0.07+0.9%$7.70$7.84$7.4237,101
$7.63+0.14+1.9%$7.70$7.70$7.421,294
$7.49-0.28-3.6%$7.84$7.98$7.493,168

Splits

6 splits since 2023 · NASDAQ:REVB · every price before a split is adjusted for it

DayRatioWhat
1-for-7Consolidation
1-for-4Consolidation
1-for-3Consolidation
1-for-16Consolidation
1-for-30Consolidation
1-for-35Consolidation
Ticker
NASDAQ:REVB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Revelation Biosciences, Inc. news

Revelation Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 54 in all · newest Nov 16, 2026 · oldest 2021
Decks
18 decks · latest November 2026

Where Revelation Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:REVB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:REVBBOATSUnited StatesUSD

Valuation

Price/book 0.3× against a median of 0.5×: 3rd lowest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$5.92M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
0.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.66

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Revelation Biosciences, Inc. · NASDAQ:REVBUS$2.39M−US$5.92Mn/an/an/a0.3×n/a0.1×1.66
Invion Ltd. · ASX:IVXUS$2.49MUS$3.12Mn/a12.2×n/a0.7×n/a0.3×n/a
GRI Bio, Inc. · NASDAQ:GRIUS$2.45M−US$6.99Mn/an/an/a0.3×n/a0.0×0.89
NeuroSense Therapeutics Ltd. · NASDAQ:NRSNUS$2.43MUS$2.20Mn/an/an/an/an/an/a1.41
ValiRx PLC · LSE:VALUS$2.42MUS$1.15Mn/a28.0×n/a0.6×n/a0.0×n/a
BSF Enterprise PLC · LSE:BSFAUS$2.40MUS$2.95Mn/a42.7×n/a1.0×n/a0.3×n/a
Mustang Bio, Inc. · NASDAQ:MBIOUS$2.38M−US$11.89Mn/an/an/a0.4×n/a0.0×1.01
Quest PharmaTech Inc. · TSXV:QPTUS$2.36MUS$2.30M0.7×n/an/a0.1×n/a0.0×1.90
HCW Biologics Inc. · NASDAQ:HCWBUS$2.35MUS$8.23Mn/a1.2×n/a0.3×−63.4%1.0×1.19
Ernexa Therapeutics Inc. · NASDAQ:ERNAUS$2.30M−US$2.96Mn/an/an/a0.5×n/a0.1×0.86
Cynata Therapeutics Limited · ASX:CYPUS$2.26MUS$1.66Mn/a1.5×n/an/a−540.4%n/an/a
Median of the othersUS$2.39MUS$1.93M0.7×12.2×0.5×−301.9%0.0×1.10

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
76.25 USD · Analysts' mean
EPS, year to Dec 2026
-33.98 · 1 analyst

Team and board

Officers

OfficerRole
James RolkeChairman, Director and Chief Executive Officer
Chester ZygmontChief Financial Officer
Carol OdleVice President, Clinical Operations
Robin MarsdenSenior Vice President, Biology

Board

DirectorRole
James RolkeChairman, Director and Chief Executive Officer
Jennifer CarverDirector
Jess Roper C.P.A.Director
Lakhmir ChawlaDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+9.3%
Q2 2026Aug 6, 2026 · After close+1.8%
Q1 2026May 7, 2026 · After close−5.9%
Q4 2025Feb 26, 2026−6.4%
Q3 2025Nov 6, 2025 · After close−2.9%
Q2 2025Aug 7, 2025−4.8%
Q1 2025May 8, 2025 · After close+2.7%
Q4 2024Mar 20, 2025 · Before open−1.4%
Q3 2024Nov 8, 2024 · After close+26.8%
Q2 2024Aug 9, 2024 · After close−7.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 10, 2024 · After close−10.7%
Q4 2023Mar 22, 2024 · After close+0.8%
Q3 2023Nov 9, 2023 · After close−3.9%
Q2 2023Aug 11, 2023 · After close−2.5%
Q1 2023May 22, 2023 · Before open+7.2%
Q4 2022Mar 30, 2023 · After close−3.7%
Q3 2022Nov 10, 2022 · After close−1.2%
Q2 2022Aug 15, 2022 · After close−5.8%
Q1 2022May 16, 2022 · Before open−4.4%
Quarter to Sep 30, 2021Oct 29, 2021 · After close0.0%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck17 slidesNovember 2026
Investor Presentation (June 2026)Investor deck19 slidesJun 1, 2026
Investor Presentation (June 2026)Investor deck23 slidesJune 2026
Investor Presentation (February 2026)Investor deck28 slidesFeb 26, 2026
Technical Presentation (September 2025)Technical26 slidesSep 9, 2025
Investor Presentation (June 2025)Investor deck8 slidesJun 25, 2025
Investor Presentation (March 2025)Investor deck22 slidesMar 17, 2025
Investor Presentation (February 2025)Investor deck23 slidesFeb 11, 2025
29th International Conference on Advances in Critical Care Nephrology: AKI and CRRT 2024Conference5 slidesMar 12, 2024
Investor Presentation (January 2024)Investor deck26 slidesJan 30, 2024
All 18 decks
DeckKindSlidesDate
Investor Presentation (October 2023)Investor deck27 slidesOct 12, 2023
Investor Presentation (May 2023)Investor deck27 slidesMay 25, 2023
Investor Presentation (January 2023)Investor deck28 slidesJan 10, 2023
Investor Presentation (October 2022)Investor deck18 slidesOct 6, 2022
Investor Presentation (March 2022)Investor deck25 slidesMar 15, 2022
Investor Presentation (February 2022)Investor deck12 slidesFeb 11, 2022
Investor Presentation (January 2022)Investor deck36 slidesJan 13, 2022
Petra Acquisition — SPAC Merger (August 2021)SPAC merger39 slidesAug 31, 2021

Open Decks

Financings

RaiseDate
Public offering of common stock (or common stock equivalents) and warrants
Closed: US$4M raised · US$1.1 a share · Warrants at US$1.1 for 60 months · Roth Capital Partners
Dealers: Roth Capital Partners (lead)
Use of proceeds: Product candidate development incl. Phase 1b study, clinical drug supply, preclinical work, other products, working capital
May 29, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as Petra Acquisition Inc., a blank check company (SPAC). Priced at US$10.00 a unit on Oct 7, 2020.

Price
US$10.00 a unit
Units offered
7,000,000 units
Offering size
US$70 million
Underwriters' option
Up to 1,050,000 more units
Listing
PAICU on the Nasdaq Capital Market
Underwriters
LifeSci Capital LLC, Ladenburg Thalmann, Northland Securities, Inc., Ingalls & Snyder LLC. · In the order on the cover
Units delivered
On or about Oct 13, 2020

Steps

StepWhen
Draft sent to the SEC in confidenceMay 14, 2020
Filed publiclyJul 29, 2020
Amended 4 timesNewest Sep 21, 2020
Shares registered with an exchangeOct 7, 2020
Declared effective by the SECOct 7, 2020
Final prospectus, with the priceOct 13, 2020

Open IPO · From the cover of the final prospectus (424B4) filed Oct 13, 2020

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000095.8M85.1M74.0M48.8M
Cost of revenue27.1K27.9K25.0K40.0K69.2K000
Gross profit-27.1K-27.9K-25.0K-40.0K-69.2K90.9M81.0M70.8M45.2M
Research and development4.06M3.55M4.15M5.38M6.91M2.56K
Selling, general and administrative5.01M4.43M4.51M5.49M5.04M145.5K36.3M34.0M31.3M21.5M
Operating income-9.07M-7.98M-8.66M-10.9M-12.0M-145.5K-3.64K38.9M32.7M18.8M
Depreciation and amortization27.1K27.9K25.0K25.0K16.8K3.80M1.75M1.49M1.62M856.0K
EBITDA-9.04M-7.95M-8.63M-10.8M-11.9M3.65M1.74M40.4M34.3M19.6M
Interest expense35.0K41.8K00000
Income before tax-8.91M-15.0M-120.3K-10.8M-12.0M-1.63M-3.64K37.1M29.8M14.9M
Income tax00000-3.80K-171.9K9.43M13.6M6.14M
Net income-8.91M-15.0M-120.3K-10.8M-12.0M-1.63M-3.64K27.6M16.3M8.78M
Earnings per share, basic-23.95-1,052.16-8.44-149.20-42.50-0.68-0.00
Earnings per share, diluted-23.95-1,052.16-8.44-149.20-42.50-0.68

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents10.7M6.50M12.0M5.25M1.27M11.7K147.1M136.4M72.2M111.5M
Short-term investments6.49B525.3K185.7M187.6M163.2M139.6M
Receivables7.67M6.85M5.87M4.98M
Current assets10.8M6.57M12.1M5.41M1.91M651.3K22.7K143.3M78.1M
Property, plant and equipment18.1K56.3K65.1K90.1K115.2K21.2M4.28M4.23M
Goodwill26.8M26.8M26.8M26.3M
Total assets11.6M6.62M12.2M5.50M2.04M74.2M22.7K2.46B2.10B1.89B
Accounts payable577.5K783.6K1.36M554.2K596.3K33.8K1.60M1.32M929.0K897.0K
Current liabilities2.00M1.91M5.56M4.45M2.14M3.43M26.3K2.12B1.80B
Long-term debt174.2M94.2M108.4M116.5M
Total debt746.8K16.8K
Total liabilities2.72M1.91M5.56M4.45M2.14M6.34M26.3K2.19B1.91B1.73B
Shareholders' equity8.86M4.71M6.65M1.05M-99.5K3.41M-3.64K264.9M188.3M168.8M
Shares outstanding226.3K43.5K16.5K77.4K282.0K1.82M1.82M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-8.27M-18.3M-7.29M-11.2M-11.1M-216.7K41.1M32.6M24.2M11.6M
Capital spending0-19.2K-4-4-132.0K-4-526.0K-861.0K-804.0K-582.0K
Free cash flow-8.27M-18.3M-7.29M-11.2M-11.2M-215.1K40.6M31.7M23.4M11.0M
Cash from investing-19.2K-132.0K-74.0M-294.9M-251.6M-196.7M
Cash from financing12.5M12.8M14.0M15.2M8.00M74.3M338.2M328.0M186.7M270.0M
Dividends paid-5.95B-7.65M
Share buybacks0-5.00K-7.65M-35.5M
Change in cash4.20M-5.49M6.74M3.98M-3.22M11.7K10.7M65.7M-40.6M84.9M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 13, 2026Current reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportAug 19, 2026Management or board changeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
4 · Change in ownershipAug 18, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 6, 2026ResultsSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
8-A12B · Registration of shares for listing on an exchangeJul 13, 2026Other filingsSEC
8-K · Current reportJul 13, 2026Material contractSEC
8-K · Current reportJun 24, 2026Management or board changeSEC
8-K · Current reportJun 1, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
DEF 14A · Proxy statementMay 11, 2026Meeting noticeSEC
ARS · Annual report to shareholdersMay 11, 2026Annual reportSEC
8-K · Current reportMay 7, 2026ResultsSEC
10-Q · Quarterly reportMay 7, 2026Quarterly reportSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
4 · Change in ownershipMay 1, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 30, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansApr 15, 2026Offer documentSEC
8-K · Current reportMar 19, 2026Meeting outcomeSEC
8-K · Current reportFeb 26, 2026ResultsSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
DEF 14A · Proxy statementFeb 17, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveFeb 12, 2026Other filingsSEC
424B3 · ProspectusFeb 11, 2026Offer documentSEC
CORRESP · Letter to the SECFeb 9, 2026Other filingsSEC
PRE 14A · Preliminary proxy statementFeb 6, 2026Meeting noticeSEC
UPLOAD · Letter from the SECFeb 6, 2026Other filingsSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
S-3 · Registration statementJan 30, 2026Offer documentSEC
8-K · Current reportJan 28, 2026Material contractSEC
8-K · Current reportJan 21, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 20, 2026Big-stake noticeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportDec 3, 2025Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansNov 12, 2025Offer documentSEC
DEF 14A · Proxy statementNov 10, 2025Meeting noticeSEC
8-K · Current reportNov 6, 2025ResultsSEC
10-Q · Quarterly reportNov 6, 2025Quarterly reportSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
4 · Change in ownershipOct 31, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementOct 31, 2025Meeting noticeSEC
8-K · Current reportOct 29, 2025Current reportSEC
8-K · Current reportOct 15, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveOct 1, 2025Other filingsSEC
424B3 · ProspectusSep 30, 2025Offer documentSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
CORRESP · Letter to the SECSep 29, 2025Other filingsSEC
S-3/A · Registration statement, amendedSep 29, 2025Offer documentSEC
UPLOAD · Letter from the SECSep 24, 2025Other filingsSEC
DEF 14A · Proxy statementSep 22, 2025Meeting noticeSEC
S-3 · Registration statementSep 16, 2025Offer documentSEC
8-K · Current reportSep 15, 2025Material contractSEC
PRE 14A · Preliminary proxy statementSep 12, 2025Meeting noticeSEC
8-K · Current reportSep 9, 2025Current reportSEC
8-K · Current reportAug 8, 2025ResultsSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportJul 9, 2025Current reportSEC
8-K · Current reportJun 25, 2025Meeting outcomeSEC
DEF 14A · Proxy statementJun 9, 2025Meeting noticeSEC
8-K · Current reportJun 4, 2025Material contractSEC
PRE 14A · Preliminary proxy statementMay 29, 2025Meeting noticeSEC
424B3 · ProspectusMay 29, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 29, 2025Other filingsSEC
8-K · Current reportMay 28, 2025Management or board changeSEC
CORRESP · Letter to the SECMay 23, 2025Other filingsSEC
S-1/A · Registration statement, amendedMay 23, 2025Offer documentSEC
CORRESP · Letter to the SECMay 22, 2025Other filingsSEC
CORRESP · Letter to the SECMay 22, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 21, 2025Other filingsSEC
CORRESP · Letter to the SECMay 20, 2025Other filingsSEC
S-1 · Registration statementMay 20, 2025Offer documentSEC
8-K · Current reportMay 8, 2025ResultsSEC
10-Q · Quarterly reportMay 8, 2025Quarterly reportSEC
UPLOAD · Letter from the SECApr 9, 2025Other filingsSEC
DRS · Draft registration statementApr 4, 2025Offer documentSEC
8-K · Current reportMar 17, 2025Current reportSEC
8-K · Current reportMar 6, 2025ResultsSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
8-K · Current reportFeb 24, 2025Current reportSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
4 · Change in ownershipFeb 13, 2025Insider tradeSEC
8-K · Current reportFeb 11, 2025Current reportSEC
8-K · Current reportJan 30, 2025Current reportSEC
8-K · Current reportJan 21, 2025Meeting outcomeSEC
DEFA14A · Additional proxy materialJan 13, 2025Meeting noticeSEC
8-K · Current reportJan 7, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 2, 2025Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveDec 23, 2024Other filingsSEC
424B3 · ProspectusDec 20, 2024Offer documentSEC
CORRESP · Letter to the SECDec 20, 2024Other filingsSEC
CORRESP · Letter to the SECDec 19, 2024Other filingsSEC
S-3/A · Registration statement, amendedDec 19, 2024Offer documentSEC
UPLOAD · Letter from the SECDec 18, 2024Other filingsSEC
DEF 14A · Proxy statementDec 16, 2024Meeting noticeSEC
8-K · Current reportDec 12, 2024Current reportSEC
S-3 · Registration statementDec 12, 2024Offer documentSEC
8-K · Current reportDec 6, 2024Material contractSEC
PRE 14A · Preliminary proxy statementDec 5, 2024Meeting noticeSEC
8-K · Current reportNov 8, 2024ResultsSEC
10-Q · Quarterly reportNov 8, 2024Quarterly reportSEC
8-K · Current reportOct 21, 2024Current reportSEC
8-K · Current reportSep 27, 2024Current reportSEC
UPLOAD · Letter from the SECSep 25, 2024Other filingsSEC
10-Q/A · Quarterly report, amendedSep 23, 2024Quarterly reportSEC
10-Q/A · Quarterly report, amendedSep 23, 2024Quarterly reportSEC
10-K/A · Annual report, amendedSep 23, 2024Annual reportSEC
CORRESP · Letter to the SECSep 23, 2024Other filingsSEC
424B3 · ProspectusSep 13, 2024Offer documentSEC
UPLOAD · Letter from the SECSep 13, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveSep 13, 2024Other filingsSEC
CORRESP · Letter to the SECSep 10, 2024Other filingsSEC
UPLOAD · Letter from the SECSep 9, 2024Other filingsSEC
S-3 · Registration statementSep 3, 2024Offer documentSEC
8-K · Current reportAug 26, 2024Material contractSEC
8-K · Current reportAug 19, 2024Current reportSEC
8-K · Current reportAug 9, 2024ResultsSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportAug 2, 2024Current reportSEC
EFFECT · Notice that a registration is effectiveJul 29, 2024Other filingsSEC
CORRESP · Letter to the SECJul 23, 2024Other filingsSEC
UPLOAD · Letter from the SECJul 23, 2024Other filingsSEC
S-3 · Registration statementJul 19, 2024Offer documentSEC
8-K · Current reportJun 24, 2024Current reportSEC
S-8 · Registration statement for employee plansJun 18, 2024Offer documentSEC
8-K · Current reportMay 16, 2024Meeting outcomeSEC
8-K · Current reportMay 10, 2024ResultsSEC
10-Q · Quarterly reportMay 10, 2024Quarterly reportSEC
DEF 14A · Proxy statementApr 15, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 5, 2024Meeting noticeSEC
8-K · Current reportMar 22, 2024ResultsSEC
10-K · Annual reportMar 22, 2024Annual reportSEC
8-K · Current reportMar 11, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 13, 2024Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
8-K · Current reportFeb 8, 2024Material contractSEC
424B3 · ProspectusFeb 2, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveFeb 1, 2024Other filingsSEC
8-K · Current reportJan 30, 2024Current reportSEC
CORRESP · Letter to the SECJan 30, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 30, 2024Offer documentSEC
S-1/A · Registration statement, amendedJan 29, 2024Offer documentSEC
CORRESP · Letter to the SECJan 29, 2024Other filingsSEC
8-K · Current reportJan 23, 2024Current reportSEC
8-K · Current reportJan 22, 2024Meeting outcomeSEC
SC 13G · Big-stake noticeJan 3, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECJan 2, 2024Other filingsSEC
DEF 14A · Proxy statementDec 22, 2023Meeting noticeSEC
S-1 · Registration statementDec 22, 2023Offer documentSEC
PRE 14A · Preliminary proxy statementDec 12, 2023Meeting noticeSEC
4 · Change in ownershipDec 12, 2023Insider tradeSEC
8-K · Current reportNov 13, 2023ResultsSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
4 · Change in ownershipOct 18, 2023Insider tradeSEC
4 · Change in ownershipOct 17, 2023Insider tradeSEC
8-K · Current reportOct 12, 2023Current reportSEC
3 · Initial statement of ownershipOct 2, 2023Insider tradeSEC
8-K · Current reportOct 2, 2023Management or board changeSEC
4 · Change in ownershipOct 2, 2023Insider tradeSEC
144 · Notice of proposed saleSep 28, 2023Other filingsSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
8-K · Current reportAug 11, 2023ResultsSEC
S-8 · Registration statement for employee plansAug 11, 2023Offer documentSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
8-K · Current reportAug 11, 2023Current reportSEC
8-K · Current reportJul 14, 2023Meeting outcomeSEC
DEFA14A · Additional proxy materialJul 7, 2023Meeting noticeSEC
8-K · Current reportJul 7, 2023Current reportSEC
8-K · Current reportJun 29, 2023Current reportSEC
DEFA14A · Additional proxy materialJun 15, 2023Meeting noticeSEC
8-K · Current reportJun 12, 2023Current reportSEC
8-K · Current reportMay 25, 2023Current reportSEC
8-K · Current reportMay 22, 2023ResultsSEC
10-Q · Quarterly reportMay 22, 2023Quarterly reportSEC
NT 10-Q · Late filing noticeMay 15, 2023Explanation requestSEC
DEF 14A · Proxy statementMay 5, 2023Meeting noticeSEC
PRE 14A · Preliminary proxy statementApr 25, 2023Meeting noticeSEC

This page holds 200 of 390 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Revelation Biosciences, Inc.’s releases · as of Nov 2, 2026

Common shares
683,442
Fully diluted
683,442

Fully diluted

LineSharesAs of
Common shares683,442Nov 2, 2026

Warrants and options

Lot
Warrants · US$1.10 · expire about May 2030

Share count over time

CountShares
Nov 2, 2026683,442
Oct 16, 2026

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Sabby Management, LLC127K18.6%US$104KSep 30, 2026
Citadel99,43114.5%US$81,235Sep 30, 2026
Susquehanna18,9282.8%US$15,464Sep 30, 2026
Geode Capital17,1922.5%US$14,045Sep 30, 2026
UBS13,2821.9%US$10,852Sep 30, 2026
Vanguard13,1271.9%US$10,725Sep 30, 2026
Tower Research Capital LLC (TRC)3,8880.57%US$3,176Sep 30, 2026
RBC8550.13%US$1,000Sep 30, 2026
BNP Paribas9<0.01%US$7Sep 30, 2026
Citigroup Inc6<0.01%US$5Sep 30, 2026
All 12 holders
HolderSharesOf the companyValueAs of
Caitong International Asset Management Co., Ltd1<0.01%US$1Sep 30, 2026
Fidelity00.00%Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Fidelity Extended Market Index Fund42,3736.2%US$46,610May 31, 2026
Blackstone Alternative Multi-Strategy Fund50<0.01%US$52Jun 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Anthony C. Hayes
Other companies: SIM Acquisition Corp. I (Director · Since at least Mar 7, 2026); Dominari Holdings Inc. (CEO & Chairman of the Board · Since at least Sep 10, 2013); Hoth Therapeutics, Inc. (Director · Feb 14, 2019 – Dec 31, 2019 · Past)
Director · Oct 7, 2020 – Oct 7, 2020 · Past
David Dobkin
Other companies: LifeSci Acquisition II Corp (Chief Financial Officer, Director · Nov 20, 2020 – Nov 20, 2020 · Past)
Director · Oct 7, 2020 – Oct 7, 2020 · Past
James Rolke
Other companies: La Jolla Pharmaceutical Co (Chief Scientific Officer · Jan 1, 2017 – May 29, 2020 · Past)
Chairman, Director and Chief Executive Officer · Since at least Jan 10, 2022
Carol OdleVice President, Clinical Operations · Since at least Nov 5, 2026
Chester Stanley Zygmont IIIChief Financial Officer · Since at least Apr 30, 2026
Chester ZygmontChief Financial Officer · Since at least Aug 18, 2026
Jennifer CarverDirector · Since at least Aug 17, 2026
Jess RoperDirector · Since at least Aug 18, 2026
Kimon AngelidesDirector · Oct 7, 2020 – Oct 7, 2020 · Past
Lakhmir ChawlaDirector · Since at least Sep 27, 2023
All 11 people
PersonSeat
Robin MarsdenSenior Vice President, Biology · Since at least Jan 14, 2026

Open People

Log in to ask 6ix AI your own questions about Revelation Biosciences, Inc.